Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The FDA-approved U.S. label says BREXAFEMME TM was initially approved in 2021 and is indicated in adult and post-menarchal pediatric females for treatment of vulvovaginal candidiasis. The same label also includes a second FDA-approved indication for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Ibrexafungerp can be administered orally once daily for Vulvovaginal Candidiasis. It shows high tissue penetration and increased activity at low pH in the vagina. The risks for c…